LQDA
Drug Manufacturers - Specialty & Generic · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when Liquidia Corp publishes a filing, an earnings call transcript or a press release.
Get LQDA alertsThe proxy statement of Liquidia Corp reports total compensation of $2,916,844 for Rajeev Saggar in fiscal 2025, including a base salary of $539,349. Disclosed compensation is on record for 3 fiscal years. Rajeev Saggar has spoken on 1 earnings call across 1 company, most recently for Liquidia Corp on March 5, 2026. Liquidia Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Liquidia Corp includes Damian deGoa (CEO and Board Member), Joanna Horobin (CEO), Paul B. Manning (CEO and Board Member) and 7 others.
“So, obviously, you know, systemic sclerosis is a rare condition overall. overall, and obviously by the nature of their actual topic of systemic means they have multiple disorders affecting multiple organ dysfunctions, inclusive of the most deadly, which is PAH and PHLD.”
Proxy statement
Start not stated–present
Last confirmed April 24, 2026
LQDA
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Liquidia Corp (LQDA) | Chief Medical Officer | $539,349 | $2,916,844 |
| 2024 | Liquidia Corp (LQDA) | Chief Medical Officer | $523,640 | $2,139,361 |
| 2023 | Liquidia Corp (LQDA) | Chief Medical Officer | $503,500 | $1,847,176 |